Kornimate/medical-research-clean huggingface dataset:
transition from acute to chronic pain after inguinal hernia, hysterectomy and thoracotomy: analysis of risk factors and association with genetic polymorphisms

Conditions: Chronic Postoperative Pain

Summary: the treatment of postoperative pain continues to be inadequate in the investigators practice setting. inadequate pain treatment not only contributes to postoperative complications in the short term but can also be a factor that favors the development of chronic postoperative pain and diminishes long-term quality of life. risk factors that can lead to a transition to chronic pain need to be analyzed.


Eligibility criteria:
inclusion criteria: * patients with given inform consent, aged mor than 18 years, who undergo scheduled surgery of one of the following types: inguinal hernia (men), hysterectomy, thoracotomy (men). exclusion criteria: * patients aged less than 18 years, * patients requiring reoperation because of surgical complications.

Keywords: chronic pain genetic polymorphisms postoperative pain
the relationship between neuropathic complaints and central sensitization in fibromyalgia

Conditions: Central Sensitisation; Fibromyalgia; Neuropathic Pain

Summary: fibromyalgia (fm) is the prototype of a group of diseases known as central sensitivity syndromes, whose relationship with pain sensitization is well defined. central sensitization (cs) is also one of the mechanisms involved in the pathophysiology of neuropathic pain. neuropathic pain, which is a common complaint in fm patients, is likely to be one of the clinical manifestations of central sensitization. therefore, in this study, it was aimed to investigate the relationship between cs and neuropathic pain.

the term central sensitization (cs) was first used by wolf in 1988 and explained as an increase in pain sensitivity with the amplification of neuron-derived signals in the central nervous system. fibromyalgia (fm) is a disease characterized by chronic widespread pain and its etiology and pathophysiology are still unknown. it is considered to be the main member of the cs related disease group known as central sensitivity syndromes with impaired pain regulation. in various studies, hyperalgesia and allodynia, which are accepted as objective findings of cs in pain sensitization. in addition to widespread body pain, neuropathic pain is one of the common symptoms in fm, and various studies have shown a significant increase in neuropathic pain in fm patients compared to healthy controls. it is known that cs is one of the basic mechanisms in the etiopathogenesis of neuropathic pain as well as its role in fm. in a study of fm patients, paindetect and s-lanss scores were found to be correlated with csi scores, and the authors emphasized the relationship between pain sensitization and neuropathic complaints in these patients. cs seems likely to be one of the neuropathic pain mechanisms in fm patients, and the available data seem insufficient to draw a definitive conclusion. from this point of view, in this study, it was aimed to investigate the relationship between the presence and severity of cs and the neuropathic pain component of the disease in patients with fm.

Eligibility criteria:
inclusion criteria: * diagnosing fibromyalgia according to acr 2016 criteria * between the ages of 18-65 * agree to participate in the study exclusion criteria: * history of concomitant systemic inflammatory disease, active infection and malignancy * refusing to participate in the study * polyneuropathy, entrapment neuropathy, and radiculopathy are other diagnosed sources of neuropathic pain.
prophylactic antibiotic use in transarterial chemoembolization for hepatocellular carcinoma

Conditions: Antibiotic Prophylaxis

Summary: this study aims to determine the effectiveness of prophylactic antibiotic use for tace and occurrence of postoperative liver abscess. there would be two comparison groups. current standard of care treatment at pkli\&rc (as per local guidelines) would be given to all patients receiving tace for the intervention group or 'antibiotic group' (i.e., inj. ceftriaxone 1g, intravenous × stat). while no antibiotic would be given to the 'no antibiotic group'.

liver cancer especially hepatocellular carcinoma (hcc) is among the top five most common carcinomas in the world. according to the latest cardiovascular and interventional radiological society of europe (cirse) standards of practice guidelines (2021), routine antibiotic prophylaxis is not recommended. however, prophylactic antibiotics are recommended in cases where there is a high risk of developing a liver abscess. these include biliary obstruction or the presence of a bilioenteric anastomosis. this study aims to determine the effectiveness of prophylactic antibiotic use for tace and occurrence of postoperative liver abscess.

Eligibility criteria:
inclusion criteria: 1. diagnosis of primary liver cancer or hepatocellular carcinoma. 2. patients receiving tace in pkli \& rc. 3. patients giving informed consent. exclusion criteria: 1. receiving two or more tace during the same hospitalization 2. use of any antibiotics other than the prophylactic antibiotic in 48hours prior to tace 3. known hypersensitivity to specified antibiotic used in the study 4. incomplete or missing laboratory investigations and data 5. taking sorafenib before tace 6. tace combined with ablation or immunetherapy 7. tumor size \>10 cm 8. portal vein thrombosis 9. dilated biliary channels on ct scan / billiary invasion by tumor

Keywords: antibiotic tace hcc
burnout among members of aagl

Conditions: Burnout, Professional

Summary: this study seeks to determine the burnout rate among minimally invasive gynecologic surgeons (migs) as well as to evaluate other personal, professional, and psychosocial factors associated with this condition. an anonymous electronic survey will be sent to the american association of gynecologic laparoscopists (aagl) members. the survey will contain items that will inquire about socioeconomic background, professional characteristic, and about physical and psychologic well-being.


Eligibility criteria:
inclusion criteria: * members of the aagl exclusion criteria: * not a member of the aagl
reach hope intervention for dementia and tbi caregivers

Conditions: Dementia, Mixed; Dementia of Alzheimer Type; TBI (Traumatic Brain Injury)

Summary: this three-year randomized clinical trial will evaluate a behavioral intervention for caregivers of veterans with traumatic brain injury (tbi) and alzheimer's dementia or mixed dementia (ad/md) to reduce caregiver depression, anxiety and burden, and improve veterans' health management. the study will combine and deliver two award-winning behavioral interventions - reach va (resources for enhancing all caregivers health in department of veterans affairs) and the dod's virtual hope box, which we call reach hope. both reach and hope box have evidence of effectiveness individually but have not been delivered together for caregivers supporting veterans with complex neurodegenerative diagnoses and health conditions. our primary hypothesis is that reach hope will improve caregivers' quality of life as measured by reduced burden.


Eligibility criteria:
inclusion criteria: * primary caregiver for person with diagnosis of tbi and subsequent dementia * at least one activity of daily living limitation or 2 or more instrumental activity of daily living limitation * provide 4 or more hours of care per day for at least 6 months * endorse a score of at least high burden (\>8) on the zarit burden inventory-4 exclusion criteria: * no mobile telephone or electronic device that can accept the hope box application * current diagnosis of schizophrenia or other major mental illness * auditory impairment that would make telephone use difficult
comparative study between espb versus iv morphine as postoperative analgesia after spine surgeries .

Conditions: Discectomy; Vertebral Fractures

Summary: postoperative pain is often severe in patients undergoing lumbar surgery. due to postoperative pain, patients are unwilling to get out of bed at an early stage, which affects their recovery. erector spinae plane block (espb) as a new trunk fascia block technique was proposed in 2016. espb has aroused the interest of many nerve block experts. the benefits of espb are not yet demonstrated. the specific mechanism is still controversial. the erector spinae block is achieved by injecting the local anesthetic solution (with possible adjuvants) between the erector spinae muscles (iliocostalis, longissimus, spinalis/ from lateral to medial) and the transverse process . the technique is performed under ultrasound guidance.


Eligibility criteria:
inclusion criteria: * lumbar disc prolapse. * fracture lumbar vertebrae exclusion criteria: 1. patient refusal. 2. drug abuse. 3. patient with significant neurological, psychiatric or neuromuscular disease. 4. chronic pain on medicine. 5. known allergy to the study medications. 6. infection at the site of infiltration. 7. patients with bleeding tendency.
incidence and outcome of reintubation in the pacu

Conditions: Postoperative Complications; Complication of Medical Care

Summary: this study evaluated the occurrence of reintubation after planned extubation (rap), the impact of rap on duration of pacu stay,length of stay,length of postoperative stay,inpatient healthcare costs, unanticipated icu admission and readmission.

the study was carried out in wuhan city, china at a general public university hospital with 62 clinical departments, 99 surgical rooms, and 38 beds in the pacu. the total number of operations performed in this hospital is more than 90,000/year. the study was approved by the hospital ethics committee and was deemed that written patient consent was not required. the adverse events, including rap, in all patients in the pacu were recorded on a standardized form in a database by pre-trained qualified nurses and/or anesthesiologists at the time of care from january 1, 2017 to december 31, 2019. data, including patient demographic and surgical and anesthesia parameters, were obtained from the anesthesia information system. adverse events management and duration of pacu stay were also documented. for three years, all collected data were filed in a computer every day and were summarized and analyzed every month. data, such as demographics, airway, oxygen saturation, consciousness, treatment, vital signs, and fast-track criteria scores, were recorded for all patients in the pacu. the first part contained preoperative and intraoperative data, which were entered into the database by the anesthesiologists involved in the patients' intraoperative care from the time of pacu admission. the second part were recorded by nurse and comprised postoperative data from the pacu to the ward or icu. the third part were recorded by the surgeons and/ or surgical nurses and comprised postoperative data. the criteria for tracheal extubation in the operating room(or) and the timing of transfer to the pacu were the responsibility of the anesthesiologist.

Eligibility criteria:
inclusion criteria: * patients requiring stay in pacu exclusion criteria: * patients were transferred directly from the operating room to the ward or icu * non-postoperative patient

Keywords: general anesthesia postanesthesia care unit reintubation after planned extubation
30-day trial of oral valtrex or valtrex plus aspirin on shedding of hsv dna in tears and saliva of volunteers

Conditions: Herpes Simplex

Summary: the purpose of this study is to determine whether oral valtrex alone or in combination with aspirin will reduce the shedding of herpes simplex virus dna in the tears and saliva from volunteers with no evidence of ocular herpes infection. the secretion of virus into the tears and saliva might make people more susceptible to virus infection in the future if their immune system becomes deficient. the study will also try to determine if there is a correlation between shedding of viral dna and herpes virus antibodies in serum and to determine if subjects are carriers of a special form of a gene in their blood cells, the presence of which may suggest the possibility of an increased susceptability to herpes and to alzheimer's disease and heart disease.

published studies have shown that treatment with oral acyclovir reduced clinical recurrences of ocular herpetic keratitis by about 40-50 %8, and treatment with valacyclovir, a more soluble prodrug of acyclovir, reduced the risk of transmission of genital herpes9, 10, 11. for this study, we will use the dose of valacyclovir that was shown effective in reducing the risk of transmission of hsv-2.9 the dose of 325 mg aspirin three times a day was chosen based on our experience with mice and other laboratory animals12. if it is effective and well tolerated at this dose, in future studies we will attempt to use lower doses and determine if they too may be effective.

Eligibility criteria:
inclusion criteria: * either sex * any race * over age of 21 years exclusion criteria: * have active ocular herpetic lesion * had ocular herpetic lesion in past 30 days * taking systemic or oral antiviral drugs * have taken antiviral drugs in the past 30 days * taking aspirin or nsaids * have dry eyes * have hypersensitivity to acyclovir or valacyclovir * have hypersensitivity of contraindication to use of aspirin * have bleeding disorder * have gi ulcer * have kidney impairment * are pregnant or nursing * have participated in a clinical trial in the past 30 days

Keywords: hsv dna volunteers
two fraction prostate sbrt with dil sib

Conditions: Prostate Cancer

Summary: phase i/ib, single arm trial of two-fraction stereotactic body radiation therapy (sbrt) with an mri directed, dominant intraprostatic lesion (dil), simultaneous integrated boost (sib) based on genomic classification in the treatment of localized prostate cancer. the primary purpose of this study is to determine the feasibility and safety of two fraction sbrt in patients with localized prostate cancer.


Eligibility criteria:
inclusion criteria: * patient age greater than or equal 18 * localized adenocarcinoma of the prostate * biopsy-proven diagnosis of prostate adenocarcinoma * low to intermediate risk national comprehensive cancer network (nccn) disease * tx-t2c-8th addition staging * psa\<20 ng/ml * grade group 3 or less * proper rectal space replacement required as determined by the treating radiation oncologist * prostate size less than 60cc defined at time of simulation based on mri * patient ability to undergo mri and documented dominant prostate imaging reporting and data system (pi-rads) 3 or higher lesion -- exception is very low risk, low risk, or favorable intermediate risk with a low to intermediate decipher score in which case an sib is not utilized * androgen-deprivation therapy (adt) is left to the discretion of the treating radiation oncologist * agreement to use effective contraceptive methods such as condoms and spermicidal foam, intrauterine device, or for their partner to use prescription birth control pills * ability to give informed consent exclusion criteria: * high risk disease * pelvic lymph node involvement * prophylactic lymph node irradiation requirement as determined by the treating radiation oncologist * evidence of clinical or radiological extracapsular extension or seminal vesicle invasion * prior radiation to the pelvis * prior malignancies within the last 5 years * inability to meet pre-specified 2 fraction dvh constraints * prostate size \> 60cc as measures at treatment planning mri * active significant inflammatory bowel disease (ibd) or rheumatological disease * prior prostate surgeries * previous uro lift * transurethral resection of the prostate (turp) within 6 months of sbrt * "reasonable" urinary, bowel, and erectile function as defined by the pre-treatment epic questionnaire (\>50 overall summary score for each domain) * men of reproductive potential may not participate unless they agree to use an effective contraceptive method

Keywords: prostate cancer,sbrt,radiation treatment,cyberknife sbrt radiation treatment cyberknife
validation of useful markers generated by next generation bio-data based genome research and cohort study

Conditions: BCL2 Gene mRNA Overexpression

Summary: multiple biomarker development through validation of useful markers generated by next generation bio-data based genome research and cohort study

1. objectives the study will be performed to develop the integrated analytical methods of genomic data and clinical data and the bio-control network analysis, through which knowledge-based integrated analysis system can be developed and then biomarker for early diagnosis and treatment of pancreatic cancer and bile duct cancer, and finally the customized disease management system. also, it is to confirm the effectiveness of diagnostic chip for research purpose by applying pancreatic/bile duct cancer-specific biomarker, mirna, found through the integrated analysis of genomic data and clinical data of patients with pancreatic/bile duct cancer to the blood of patients with pancreatic/bile duct cancer. 2. effective evaluation method the discrimination and calibration for algorithm through the diagnostic chip of each cancer type will all be examined using 10-fold cross-validation (100 repetitions). in the 10-fold cross-validation, the data is randomly divided into 10 same sized data, among which 9 are used in making a model for training and the remaining 1 is applied for test, and this process is randomly and independently repeated for 100 times. the 10-fold cross-validated auc is calculated to see the discrimination of diagnostic chip of each cancer type, and the 95% confidence interval is presented by non-parametric method. the 10-fold cross-validated calibration plot is presented to see the calibration of diagnostic chip of each cancer type. the calibration plot visually demonstrate the degree of prediction by comparing the prediction probability of each group and the ratio of actual cancer patients after listing the prediction probability in the order and dividing it with regular intervals. then, for the same subjects, the auc of the ca 19-9, the existing cancer diagnostic tool, is calculated and the 95% confidence interval is presented. to compare the diagnostic chip of each cancer type and the auc of ca 19-9, p-value is calculated by non-parametric method of 10-fold cross-validated auc.

Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically diagnosed pancreatic cancer or bile duct cancer * patient age: 20\~80 years old * patients who voluntarily determined to participate in the clinical trial and signed the informed consent for compliance * korean race exclusion criteria: * patients with previous history of chemotherapy or radiation therapy for pancreatic cancer and/or bile duct cancer * patients who had treatment or surgery for cancer of other organ within 5 years before the clinical trial

Keywords: biomarker pancreatic cancer bile duct cancer mirna
quality of life after radiofrequency ablation of pancreatic cancer

Conditions: Pancreatic Cancer

Summary: a prospective clinical study evaluating quality of life (qol) in pancreatic cancer patients treated with intraoperative radiofrequency ablation (rfa).


Eligibility criteria:
inclusion criteria: * histologically proved locally advanced or metastatic pancreatic cancer. patients with histologically proved resectable pancreatic cancer with low karnofsky index. informed consent exclusion criteria: * cystic tumor age under 18
early prediction and warning for cardiotoxicity due to anthracycline-based breast cancer chemotherapy

Conditions: Breast Cancer

Summary: this multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.

the latest global cancer burden data released by the world health organization international agency for research on cancer (iarc) has shown that the incidence of breast cancer ranks first in the world. anthracycline-based treatments are first-line chemotherapy agents to treat early breast cancer. although anthracycline-based treatments has significantly improved the 5-year survival rate of breast cancer patients, the cancer therapy-related cardiac dysfunction (ctrcd) caused by anthracyclines has become the major cause of breast cancer death. however, ctrcd patients often have no obvious symptoms of heart failure in the early stage, and the diagnosis is very secretive, resulting in delayed intervention, unable to timely terminate the disease process, and seriously affecting the prognosis. echocardiography has the advantages of real-time, non-invasive and repeatable, and is the preferred detection method for asymptomatic ctrcd at present. the diagnosis of asymptomatic ctrcd depends on the change of left ventricular (lv) ejection fraction (ef) and global longitudinal strain (gls) before and after chemotherapy. however, the measurement of lvef and gls is based on manual methods, resulting in poor repeatability. cardiotoxicity due to anthracycline-based breast cancer chemotherapy progresses gradually and changes dynamically with dose and time. therefore, this study intends to build an intelligent model for early prediction and warning of asymptomatic ctrcd, so as to provide a reliable basis for timely adjustment of individualized cardiac protection strategies and maintaining lv function and reducing mortality.

Eligibility criteria:
inclusion criteria: * age ≥18 years * histologically or cytopathological confirmed stage i-iii her2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy * lvef≥53% before chemotherapy exclusion criteria: * life expectancy ≤12 months * participating in other ongoing oncology clinical trials * prior treatment with anthracyclines or chest radiation therapy * pregnant or lactating women * ultrasound images of the heart are of very poor quality

Keywords: breast cancer chemotherapy anthracyclines cardiotoxicity early detection
methylnaltrexone use for opioid-induced postoperative constipation

Conditions: Constipation

Summary: the purpose of this study is to determine whether the routine use of methylnaltrexone in the post-operative pediatric spinal fusion patient will decrease the incidence of constipation.

methylnaltrexone will be given to pediatric patients post-operative from spinal fusion surgery on post-operative day number 3 and then again on postoperative day number 4, if no laxation achieved. various outcome measures, safety and efficacy of the drug will be observed and recorded.

Eligibility criteria:
inclusion criteria: * spinal fusion surgery * current opioid use * 12 years of age and older * no or inadequate bowel movement by post-operative day 3 exclusion criteria: * known or expected mechanical bowel obstruction * known or suspected lesions of the gi tract * unexpected transfer to icu * unexpected return to the operating room * patient or parent refusal of methylnaltrexone * incomplete data concerning time to laxation

Keywords: opioid-induced